Long term results of venetoclax combined with FLAG-IDA induction and consolidation for newly diagnosed and relapsed or refractory acute myeloid leukemia.
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi...
https://pubmed.ncbi.nlm.nih.gov/40000842/Actively Recruiting
Led by M.D. Anderson Cancer Center · Updated on 2026-11-02
116
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are evaluating the best dose, side effects, and effectiveness of venetoclax combined with chemotherapy in patients with newly diagnosed or relapsedrefractory acute myeloid leukemia AML. This phase IbII trial aims to determine the safety and activity of this combination, including response rates and survival outcomes. The study also seeks to identify biomarkers that may predict venetoclaxs activity. Participants receive venetoclax orally along with a combination chemotherapy regimen called FLAG-IDA, which includes fludarabine, cytarabine, filgrastim or pegfilgrastim, and idarubicin. Treatment is given in three phases induction therapy for up to 2 cycles, consolidation therapy for up to 6 cycles, and maintenance therapy for up to 1 year, each repeated every 28 days if there is no disease progression or unacceptable toxicity. During the study, patients undergo regular assessments including blood tests, response evaluations using standardized criteria, and monitoring of side effects. Researchers measure outcomes such as overall response rate, duration of response, event-free survival, overall survival, drug exposure levels, and adverse events over up to 6 years. After treatment, patients have follow-up visits within 30 days to monitor safety and response.
CONDITIONS
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
D
DiNardo, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Venetoclax plus FLAG-IDA chemotherapy (Trial regimen) | FLAG-IDA chemotherapy alone (Current intensive regimen) |
|---|---|---|
| What it is | A combination of venetoclax (BCL2 inhibitor) plus FLAG-IDA intensive chemotherapy including fludarabine, cytarabine, G-CSF, and idarubicin, given to adults with newly diagnosed or relapsed or refractory AML or high-risk MDS. | FLAG-IDA is an established intensive chemotherapy regimen composed of fludarabine, cytarabine, G-CSF, and idarubicin, commonly used for adult AML patients, especially in relapsed or high-risk disease. |
| Role in trial | Investigational treatment given to all eligible participants to assess response and safety outcomes. | Serves as the current intensive chemotherapy backbone for eligible adults with AML, used as an established reference standard in clinical guidelines and practice. |
| Primary use | Being studied for increasing remission rates, response duration, and survival when added to intensive chemotherapy in newly diagnosed or relapsed/refractory AML or high-risk MDS. | Used for intensive induction or re-induction therapy to achieve remission in adults with AML, including relapsed/refractory and high-risk groups. |
| How it is given | Venetoclax (oral tablet) is combined with intravenous FLAG-IDA protocol: fludarabine, cytarabine, and idarubicin plus G-CSF support over defined cycles. Pegfilgrastim can be used as an alternative to filgrastim for G-CSF support. | Given as cycles of intensive intravenous chemotherapy with fludarabine, cytarabine, and idarubicin, supported by G-CSF for neutrophil recovery. Administered inpatient or in specialized centers. |
| Evidence status | Results are being studied in this ongoing clinical trial; published data show promising response rates, but confirmatory evidence and longer-term outcomes are awaited. | FLAG-IDA has established efficacy with published remission and survival rates for relapsed/refractory AML, supported by guideline recommendations for use in eligible adults. |
| Important limitations | The trial is single-arm without randomization, so effects of adding venetoclax to FLAG-IDA rely on indirect comparison to historical outcomes. High rates of cytopenias and infectious complications require close monitoring. | FLAG-IDA is also associated with significant myelosuppression and infection risks, and not all patients are candidates for intensive chemotherapy due to fitness or comorbidities. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 2 cycles of 28 days each
Participants receive venetoclax orally for 14 days along with intravenous fludarabine, cytarabine, and idarubicin, plus subcutaneous filgrastim or pegfilgrastim over 28-day cycles. This phase lasts up to 2 cycles if tolerated and no disease progression occurs.
Multiple visits during each cycle
Duration - Up to 6 cycles of 28 days each
Participants receive venetoclax on days 1-7 with fludarabine and cytarabine intravenously, plus filgrastim or pegfilgrastim subcutaneously, repeated every 28 days for up to 6 cycles. Idarubicin may be given during one consolidation cycle per physician's decision.
Multiple visits during each cycle
Duration - Up to 12 cycles of 28 days each
Participants receive venetoclax orally daily for 28 days per cycle, repeated every 28 days for up to 1 year if no disease progression or unacceptable toxicity occurs.
Regular visits during maintenance
Duration - 30 days after last treatment
After completing study treatment, participants are monitored for safety and response within 30 days.
1 follow-up visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Courtney D DiNardo, Wei-Ying Jen, Koichi Takahashi...
https://pubmed.ncbi.nlm.nih.gov/40000842/M.D. Anderson Cancer Center
Lead Sponsor
National Cancer Institute (NCI)
Collaborating Sponsor